



To:

[Redacted recipient list]

Subject: Flash: Meeting with AbbVie, 07 February 2020

Meeting with AbbVie (originator, biopharmaceutical company), 07 February 2020

Background: AbbVie is a major US-based pharmaceutical company specialised on biomedicines (AbbVie commercialises Humira® the highest selling medicine ever with around USD 20 bn a year sales most recently). This meeting took place in the context of the on-going evaluation of EU pharmaceutical incentives [Redacted] DG GROW is evaluating the SPC legislation).

Participants:

- GROW: [Redacted] (F3)
- AbbVie: [Redacted]

Discussion:

- [Redacted]
- AbbVie asked about the state of play of our reflections on the unified/single grant mechanism for SPCs.
- AbbVie welcomed the safeguards, especially the notification, included in Regulation 2019/933 on the SPC waiver. Their legal teams are aware of the Regulation and ready for monitoring.
- [Redacted]

[Redacted signature block]

Regards,

[Redacted name]